Clinical Study

Bl-8040.Scm.301- A Phase III, Randomized, Double-Blinded Placebo-Controlled, Multi-Centre Study Evaluating The Safety, Tolerability And Efficacy Of Combination Treatment Of Bl- 8040 And G-Csf As Compared To Placebo And G-Csf For The Mobilization Of Hemato

Posted Date: Oct 1, 2019

  • Investigator: Tahir Latif
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The goal of this study is To demonstrate the superiority of one dose of BL-8040 + G-CSF over placebo + G-CSF to mobilize =6.0 x 106 CD34+ cells/kg in up to 2 apheresis sessions in preparation for autologous hematopoietic cell transplantation (auto-HCT) in MM subjects.

Criteria:

To Be Eligible: Between 18-78 Years Of Age, Diagnosed With Multiple Myeloma, Nonpregnant/Nonbreastfeeding, No Other Active Infection Or Metastases

Keywords:

Multiple Mylenoma, Cancer

For More Information:

Uc Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.